| Active, not recruiting | 2 | 40 | US | Lenalidomide and bb2121, ide-cel, revlimid | Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS | Multiple Myeloma | 01/25 | 04/25 | | |
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab |
|
|
| Recruiting | N/A | 200 | US | No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment | Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research | HIV Infections, Multi-Antiviral Resistance | 12/25 | 06/26 | | |